SCHEMBL4763673

SCHEMBL4763673

COc1cc(-c2cc(CN3CCN(Cc4ccnc(-c5ccc(F)cc5)c4)CC3)ccn2)cc(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.48
HTR1A P08908 1/20 0.48
KCNH2 Q12809 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 1/20 0.47
TGFBR1 P36897 1/20 0.46
ACVR1 Q04771 1/20 0.46
JAK2 O60674 3/20 0.44
JAK1 P23458 3/20 0.44
TYK2 P29597 2/20 0.44
JAK3 P52333 2/20 0.44
MAPK1 P28482 1/20 0.44
AURKA O14965 1/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 2/20 0.43
ABCB1 P08183 1/20 0.43
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4772860 0.95 MAPK1 (0.49) DRD2HTR1AKCNH2KDM4EALDH1A1
SCHEMBL4763764 0.92 TGFBR1 (0.49) DRD2KDM4EALDH1A1TGFBR1ACVR1
SCHEMBL7165935 0.90 HDAC1 (0.50) DRD2KDM4EALDH1A1TGFBR1ACVR1
SCHEMBL4770488 0.90 TGFBR1 (0.49) KDM4EALDH1A1TGFBR1ACVR1JAK2
SCHEMBL4768772 0.89 TGFBR1 (0.48) DRD2KDM4EALDH1A1TGFBR1ACVR1
SCHEMBL4768430 0.89 POLB (0.53) DRD2ALDH1A1TGFBR1ACVR1JAK2
SCHEMBL4773743 0.88 TGFBR1 (0.53) KDM4EALDH1A1TGFBR1ACVR1JAK2
SCHEMBL7161609 0.88 HCRTR1 (0.51) DRD2ALDH1A1ACHEBACE1DRD4
SCHEMBL7160532 0.88 KDM4E (0.51) KDM4EALDH1A1HTTTGFBR1ACVR1
SCHEMBL4763891 0.88 KDM4E (0.53) KDM4EALDH1A1TGFBR1ACVR1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 DRD2 464/4885HTR1A 1774/4885KCNH2 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.